[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612603":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":45,"centralContacts":49,"locations":54,"responsibleParty":70,"collaborators":10,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":10,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"City of Hope Medical Center","OTHER",[8,14,18,23,27,31],{"label":9,"type":10,"description":11,"interventionNames":12},"High-risk Colon Cancer (Discovery)",null,"Stage IIB-IV colon cancer; used to identify biomarker candidates",[13],"Diagnostic Test: Diagnostic Test: EXPOSE assay（Small RNA-seq of exosomal miRNAs）",{"label":15,"type":10,"description":16,"interventionNames":17},"Low-risk Colon Cancer (Discovery)","Stage I-IIA colon cancer",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"High-risk Colon Cancer (Training)","Pathological Stage IIB-IV; used to build model",[22],"Diagnostic Test: Diagnostic Test: EXPOSE RT-qPCR panel",{"label":24,"type":10,"description":25,"interventionNames":26},"Low-risk Colon Cancer (Training)","Pathological Stage I-IIA",[22],{"label":28,"type":10,"description":29,"interventionNames":30},"High-risk Colon Cancer (Validation)","Stage IIB-IV in independent cohort",[22],{"label":32,"type":10,"description":33,"interventionNames":34},"Low-risk Colon Cancer (Validation)","Stage I-IIA in independent cohort",[22],[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":10},"DIAGNOSTIC_TEST","Diagnostic Test: EXPOSE assay（Small RNA-seq of exosomal miRNAs）","Candidates identified from small RNA sequencing",[9,15],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":10},"Diagnostic Test: EXPOSE RT-qPCR panel","Quantification of exosomal microRNAs (RT-qPCR)",[19,28,24,32],[46],{"name":47,"affiliation":5,"role":48},"Ajay Goel, PhD","PRINCIPAL_INVESTIGATOR",[50],{"name":47,"role":51,"phone":52,"phoneExt":10,"email":53},"CONTACT","626-218-3452","ajgoel@coh.org",[55],{"facility":5,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Duarte","California","91016","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-117.97729,34.13945,{"lat":66,"lon":65},[69],{"name":47,"role":51,"phone":52,"phoneExt":10,"email":53},{"type":71,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100612603","an-exosomal-microrna-signature-for-preoperative-staging-in-colon-cancer-100612603",false,"NCT07255729","An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer","Machine Learning-Based Exosomal microRNA Signature for Preoperative Staging and Chemotherapy Eligibility in Colon Cancer","EXPOSE","Inclusion Criteria:\n\n* Pathologically confirmed colon cancer (Stage I-IV, UICC TNM 8th edition)\n* Underwent curative-intent resection (with or without perioperative therapy)\n* Preoperative plasma (or serum) samples available\n* Clinical and prognostic data available\n\nExclusion Criteria:\n\n* No written informed consent\n* Missing preoperative blood samples\n* Missing survival\u002Frecurrence data\n* Duplicate cases\n* Non-adenocarcinoma histology","ALL","18 Years",{"count":83,"type":84},400,"ESTIMATED","OBSERVATIONAL","Recent studies have highlighted the potential benefits of neoadjuvant chemotherapy (NAC) in colon cancer; however, its indication is generally limited to cases corresponding to pathological stage IIB or higher. Accurately identifying such high-risk cases before surgery remains challenging using conventional clinical diagnostics alone. Therefore, we hypothesized that integrating molecular biomarkers with preoperative clinical assessment could provide a more precise and sensitive evaluation of tumor aggressiveness. In this context, we focused on exosomal microRNAs, which are actively secreted from tumor cells and remain stable in circulation, and aimed to develop a machine learning-based biomarker panel. To achieve this, we initiated a multicenter study utilizing preoperative plasma samples to establish a reliable biomarker model for risk stratification and treatment decision-making in colon cancer.",[88],"Colon Cancer",[90,91,92,93,94,95],"CC","NAC","miRNA","Exosomal miRNA","Staging","liquid biopsy","2026-07-06",{"date":98,"type":99},"2026-07-07","ACTUAL",{"date":101,"type":99},"2025-01-15",{"date":103,"type":84},"2028-06-18",{"name":5,"class":6},1]